Existing research has preliminarily confirmed the feasibility and potential benefits of CD19 CAR-T cell therapy for autoimmune diseases such as SSc and inflammatory myopathy, but its clinical application still faces many challenges. Here, CD19 is linked to systemic sclerosis.